SK7232002A3 - Tetrahydrothiopyranphthalazinone derivatives as pde4 inhibitors - Google Patents

Tetrahydrothiopyranphthalazinone derivatives as pde4 inhibitors Download PDF

Info

Publication number
SK7232002A3
SK7232002A3 SK723-2002A SK7232002A SK7232002A3 SK 7232002 A3 SK7232002 A3 SK 7232002A3 SK 7232002 A SK7232002 A SK 7232002A SK 7232002 A3 SK7232002 A3 SK 7232002A3
Authority
SK
Slovakia
Prior art keywords
alkoxy
compounds
formula
hydrogen
fluorine
Prior art date
Application number
SK723-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Armin Hatzelmann
Daniela Bundschuh
Hans-Peter Kley
Geert Jan Sterk
Der Laan Ivonne Johanna Van
Hendrik Timmerman
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of SK7232002A3 publication Critical patent/SK7232002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK723-2002A 1999-10-25 2000-10-24 Tetrahydrothiopyranphthalazinone derivatives as pde4 inhibitors SK7232002A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99121243 1999-10-25
US20395000P 2000-05-12 2000-05-12
PCT/EP2000/010445 WO2001030777A1 (en) 1999-10-25 2000-10-24 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors

Publications (1)

Publication Number Publication Date
SK7232002A3 true SK7232002A3 (en) 2002-09-10

Family

ID=26153155

Family Applications (1)

Application Number Title Priority Date Filing Date
SK723-2002A SK7232002A3 (en) 1999-10-25 2000-10-24 Tetrahydrothiopyranphthalazinone derivatives as pde4 inhibitors

Country Status (20)

Country Link
US (2) US6544993B1 (ja)
EP (1) EP1244654A1 (ja)
JP (1) JP2003512466A (ja)
KR (1) KR20020043238A (ja)
CN (1) CN1146562C (ja)
AU (1) AU781137B2 (ja)
BR (1) BR0014990A (ja)
CA (1) CA2388119A1 (ja)
CZ (1) CZ20021457A3 (ja)
EA (1) EA005856B1 (ja)
HK (1) HK1047276A1 (ja)
HR (1) HRP20020350A2 (ja)
HU (1) HUP0203487A2 (ja)
IL (1) IL148807A0 (ja)
MX (1) MXPA02003581A (ja)
NO (1) NO20021959L (ja)
PL (1) PL354979A1 (ja)
SK (1) SK7232002A3 (ja)
TR (1) TR200201128T2 (ja)
WO (1) WO2001030777A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020043238A (ko) * 1999-10-25 2002-06-08 빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하 Ｐｄｅ４ 억제제로서의 테트라히드로티오피란프탈라지논유도체
IL156812A0 (en) 2001-02-15 2004-02-08 Altana Pharma Ag Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
IL157908A0 (en) * 2001-04-25 2004-03-28 Altana Pharma Ag Phthalazinone derivatives and pharmaceutical compositions containing the same
IL157870A0 (en) 2001-04-25 2004-03-28 Altana Pharma Ag Piperazino derivatives and pharmaceutical compositions containing the same
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2004018449A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
JP2005538137A (ja) * 2002-08-10 2005-12-15 アルタナ　ファルマ　アクチエンゲゼルシャフト ピペリジン−ｎ−オキシド誘導体
EP1556369A1 (en) * 2002-08-10 2005-07-27 ALTANA Pharma AG Pyridazinone-derivatives as pde4 inhibitors
AU2003260376A1 (en) * 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
RS20050523A (en) * 2003-01-14 2007-09-21 Altana Pharma Ag., Pde4 inhibotors for the treatment of neoplasms of lymphoid cells
ATE390419T1 (de) 2004-02-04 2008-04-15 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-o - derivate als pde4-inhibitoren
EP1716123A1 (en) * 2004-02-04 2006-11-02 Altana Pharma AG Pyridazinone derivatives and their use as pde4 inhibitors
SG182194A1 (en) * 2004-03-03 2012-07-30 Nycomed Gmbh Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors
EP2651417B1 (en) * 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
JP6545148B2 (ja) 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ，エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204808D0 (en) * 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
EP0672031B1 (en) 1992-12-02 2003-03-12 Pfizer Inc. Catechol diethers as selective pde iv inhibitors
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
DE69811645T2 (de) * 1997-01-15 2003-12-04 Altana Pharma Ag Phtalazinonen
AU1760399A (en) * 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
EE04312B1 (et) * 1997-12-15 2004-06-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihüdrobensofuraanid, nende kasutamine ravimite valmistamiseks ning neid sisaldavad ravimid
CA2323771A1 (en) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
KR20020043238A (ko) * 1999-10-25 2002-06-08 빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하 Ｐｄｅ４ 억제제로서의 테트라히드로티오피란프탈라지논유도체

Also Published As

Publication number Publication date
MXPA02003581A (es) 2002-10-23
CN1382137A (zh) 2002-11-27
WO2001030777A1 (en) 2001-05-03
TR200201128T2 (tr) 2002-08-21
CZ20021457A3 (cs) 2002-07-17
CN1146562C (zh) 2004-04-21
EA200200381A1 (ru) 2002-10-31
HRP20020350A2 (en) 2004-02-29
US6846821B2 (en) 2005-01-25
CA2388119A1 (en) 2001-05-03
NO20021959L (no) 2002-05-29
EP1244654A1 (en) 2002-10-02
US20030166655A1 (en) 2003-09-04
EA005856B1 (ru) 2005-06-30
PL354979A1 (en) 2004-03-22
NO20021959D0 (no) 2002-04-25
HK1047276A1 (zh) 2003-02-14
IL148807A0 (en) 2002-09-12
HUP0203487A2 (hu) 2003-02-28
US6544993B1 (en) 2003-04-08
KR20020043238A (ko) 2002-06-08
AU781137B2 (en) 2005-05-05
AU1515101A (en) 2001-05-08
JP2003512466A (ja) 2003-04-02
BR0014990A (pt) 2002-06-18

Similar Documents

Publication Publication Date Title
JP4555684B2 (ja) Ｐｄｅ４阻害剤としての、ピロリジンジオンにより置換されたピペリジン−フタラゾン
US20060166995A1 (en) Piperidine-n-oxide-derivatives
SK7232002A3 (en) Tetrahydrothiopyranphthalazinone derivatives as pde4 inhibitors
NO325245B1 (no) Ftalayinon-piperidinderivater, legemidler inneholdende disse og deres anvendelse
EP1228046B1 (en) Phthalazinone derivatives as pde 4 inhibitors
US7022696B2 (en) Piperazino-derivatives and their use as PDE4 inhibitor
AU2002315311A1 (en) Piperazino-derivatives and their use as PDE4 inhibitor